December 29, 2014 3:25 AM ET

Pharmaceuticals

Company Overview of ContraVir Pharmaceuticals, Inc.

Company Overview

ContraVir Pharmaceuticals, Inc. operates as a biopharmaceutical company. It primarily focuses on the clinical development of FV-100, an orally available nucleoside analogue prodrug of CF-1743 for the treatment of herpes zoster, which is an infection caused by the reactivation of varicella zoster virus or chickenpox. The company was founded in 2013 and is headquartered in Edison, New Jersey. ContraVir Pharmaceuticals, Inc. (OTCBB:CTRV) operates independently of Synergy Pharmaceuticals, Inc. as of December 11, 2014.

399 Thornall Street

First Floor

Edison, NJ 08837

United States

Founded in 2013

3 Employees

Phone:

732-902-4000

Fax:

732-902-4100

Key Executives for ContraVir Pharmaceuticals, Inc.

Chief Executive Officer and Director
Age: 52
Total Annual Compensation: $86.2K
Chief Financial Officer
Age: 45
Total Annual Compensation: $4.9K
Compensation as of Fiscal Year 2014.

ContraVir Pharmaceuticals, Inc. Key Developments

ContraVir Pharmaceuticals, Inc. Appoints Nathaniel Katz, M.D. as Chairman of Scientific Advisory Board

ContraVir Pharmaceuticals, Inc. announced the formation of a Scientific Advisory Board to support the development of the Company's targeted antiviral therapies. The Company also announced that Nathaniel Katz, M.D. has joined ContraVir as Chairman of the newly formed SAB. Nathaniel P. Katz, M.D., M.S., is President and Chief Executive Officer of Analgesic Solutions.

ContraVir Pharmaceuticals, Inc. Initiates Pharmacokinetic Study of Lead Antiviral FV-100 for Treating Shingles

ContraVir Pharmaceuticals, Inc. announced that it has initiated a pharmacokinetic (PK) study of FV-100, the company's clinical-stage antiviral for treating shingles. The PK study, to be conducted at Duke University in early 2015, is designed to further understand the effect of a potent inhibitor of Cytochrome P450 3A4 on the pharmacokinetics of FV-100, allowing ContraVir to better understand the potential for clinically important drug-drug interactions and to further optimize treatment for Phase 3 development. FV-100 is a fast acting, low dose, once-daily oral antiviral agent being developed for the treatment of herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus. In addition to direct antiviral activity, FV-100 has demonstrated the potential to reduce the incidence of debilitating shingles-associated pain, known as post-herpetic neuralgia, or PHN. In addition to the current PK trial, ContraVir has completed planning a larger clinical study of FV-100 to confirm the previous favorable efficacy and safety results. The study is designed to measure the efficacy of FV-100 for treating Shingles and associated PHN, as measured by the incidence of clinically meaningful pain at the end of the follow-up period, as well as determine the best dose and regimen of treatment.

Contravir Pharmaceuticals, Inc. Proposes Amendment to it's Certificate of Incorporation

ContraVir Pharmaceuticals, Inc. announced that it will propose for shareholders approval at its AGM, to be held on December 02, 2014, to approve an amendment to the Company's Certificate of Incorporation to authorize the Board of Directors of the company to effect a reverse stock split of the company's common stock by a ratio of not less than 1-for-2 and not more than 1-for-5, with the Board of the company having the discretion as to whether or not the reverse split is to be effected at any time prior to the first anniversary date of this meeting of stockholders, and with the exact ratio of any reverse split to be set at a whole number within the above range as determined by the company's Board in its discretion (the Reverse Split Proposal).

Similar Private Companies By Industry

Company Name Region
Bearpot, Inc. United States
Organic Science, Inc. United States
RxElite Inc. United States
Bridge Laboratories, Inc. United States
Edunn Biotechnology, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
October 14, 2014
--
Private Placement
February 4, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ContraVir Pharmaceuticals, Inc., please visit www.contravir.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.